SEGMENT REPORTING

3 Months Ended

Mar. 31, 2025

SEGMENT REPORTING

SEGMENT REPORTING

(8) SEGMENT REPORTING

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: life science. The life science segment consists of the development of clinical and preclinical product candidates. The Company’s chief operating decision maker (“CODM”) is the chief executive officer.

The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the life science segment based on net loss, which is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets.

To date, the Company has not generated any product revenue and has incurred losses and negative cash flows from operations since inception. The Company’s future life science expenses will be significantly dependent on our ability to successfully consummate the Merger, related audit and legal expenses and whether we decide to pursue any future product development efforts.

The table below summarizes the significant expense categories regularly reviewed by the CODM for the three months ended March 31, 2025, and 2024.

	Three Months Ended March 31,
	2025		2024
Operating expenses:
Professional fees and services	$	1,778	$	1,638
Stock-based compensation		1,184		4,200
Employee costs		202		5,889
Other segment items(a)		225		319
AV-101 clinical trials		—		7,195
Chemistry, manufacturing, and controls		—		5,380
Interest income		(871)		(1,435)
Consolidated net loss	$	2,518	$	23,186
(a) Other segment items include rent and facilities related expenses.